论文部分内容阅读
[目的]研究趋化因子受体CXCR7在非小细胞肺癌(NSCLC)中的表达,并探讨其与NSCLC临床病理特征的关系。[方法]采用免疫组织化学Envision法检测120例NSCLC癌组织及20例正常肺组织中CXCR7的表达。[结果]在NSCLC癌组织中,CXCR7阳性表达率为59.2%(71/120),在正常肺组织中CXCR7阳性表达率为10.0%(2/20)(P<0.05)。CXCR7阳性表达与癌组织分化程度和淋巴结转移有关(P<0.05)。CXCR7阳性表达组与阴性表达组5年生存率分别为11.3%和22.4%(P<0.05)。[结论]CXCR7可能参与了NSCLC的发生发展和淋巴结转移。
[Objective] To investigate the expression of chemokine receptor CXCR7 in non-small cell lung cancer (NSCLC) and to explore its relationship with clinicopathological features of NSCLC. [Method] The immunohistochemical Envision method was used to detect the expression of CXCR7 in 120 NSCLC tissues and 20 normal lung tissues. [Results] The positive rate of CXCR7 expression in NSCLC was 59.2% (71/120) and the positive rate of CXCR7 in normal lung tissue was 10.0% (2/20) (P <0.05). The positive expression of CXCR7 correlated with the degree of differentiation and lymph node metastasis (P <0.05). The 5-year survival rates of CXCR7 positive group and negative group were 11.3% and 22.4%, respectively (P <0.05). [Conclusion] CXCR7 may be involved in the occurrence and development of NSCLC and lymph node metastasis.